Featured Research

from universities, journals, and other organizations

Wake Forest Researcher Reports Cholesterol-Lowering Drug Reduces Strokes

Date:
November 10, 1999
Source:
Wake Forest University Baptist Medical Center
Summary:
A drug already being used to lower cholesterol and prevent heart attacks sharply reduced strokes in patients who already had heart disease, a Wake Forest University researcher reports.

WINSTON-SALEM, N.C. - A drug already being used to lower cholesterol and prevent heart attacks sharply reduced strokes in patients who already had heart disease, a Wake Forest University researcher told the American Heart Association meeting today (Nov. 8) in Atlanta.

Robert P. Byington, Ph.D., professor and head of the Section on Epidemiology, said the drug, pravastatin, reduced stroke by 20 percent, compared to placebo, in patients with heart disease or high cholesterol.

The study "offers a major new way to lower the stroke rate," Byington said.

He said the drug reduced the risk of stroke over a wide range of cholesterol values and among a wide spectrum of patients in pooled data from three similar clinical trials. The effect occurred primarily in the patients who already had coronary heart disease, where the reduction was 22 percent.

The Prospective Pravastatin Pooling Project began in 1992, before any of the three clinical trials were completed. The three trials - WOS (West of Scotland coronary prevention study), CARE (Cholesterol And Recurrent Events) and LIPID (Long-term Intervention with Pravastatin in Ischemic Disease) totaled 19,768 participants from Scotland, the United States, Canada and Australia-New Zealand.

All were randomized clinical trials that compared 40 milligrams per day of pravastatin to an inert placebo. WOS was conducted in patients with very high cholesterol levels, while CARE and LIPID involved coronary heart disease patients. The data was collected as the studies were underway, with patients remaining in the study an average of five years.

Over the course of the three studies, a total of 267 patients on pravastatin had strokes, compared to 331 patients on the placebo, a statistically significant difference. The stroke rate declined from 6.5 per thousand per year in the placebo group to 5.2 per thousand in the pravastatin group. Most of the strokes were non-fatal; the number of fatal strokes was just about the same in both groups.

The drug prevented the type of stroke caused by the blocking of an artery in the brain, a situation similar to the blocking of a coronary artery in the heart (which leads directly to a heart attack.)

He noted that the effect on stroke was somewhat unexpected. "People have been combining the results from lipid [cholesterol] lowering trials for years and even as late as 1992, in one of the last analyses, there was zero difference in strokes between the groups that were on lipid-lowering drugs and the people who were on placebo."

These earlier studies were done with other kinds of drugs that lower cholesterol. When the class of drugs called statins became available in the late 1980s, "we began seeing a much larger reduction in lipid levels, and amazingly, hints of reduction in stroke - and we weren't expecting to see that at all."

The new study is strong evidence that pravastatin reduces strokes.

About 600,000 people suffer a non-fatal strokes each year in the United States, and these strokes are a leading cause of serious long-term disability and extensive and expensive rehabilitation.

The Prospective Pravastatin Pooling Project was funded by Bristol Myers Squibb, as were WOS, CARE and LIPID.


Story Source:

The above story is based on materials provided by Wake Forest University Baptist Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Wake Forest University Baptist Medical Center. "Wake Forest Researcher Reports Cholesterol-Lowering Drug Reduces Strokes." ScienceDaily. ScienceDaily, 10 November 1999. <www.sciencedaily.com/releases/1999/11/991110061850.htm>.
Wake Forest University Baptist Medical Center. (1999, November 10). Wake Forest Researcher Reports Cholesterol-Lowering Drug Reduces Strokes. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/1999/11/991110061850.htm
Wake Forest University Baptist Medical Center. "Wake Forest Researcher Reports Cholesterol-Lowering Drug Reduces Strokes." ScienceDaily. www.sciencedaily.com/releases/1999/11/991110061850.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins